SBIR/STTR Research Award

Apoptotic Regulation of Lymphocyte Responses

Award identifier b4479027114aeb762d818030536348c544cd3d4a34fbc07550471ef8834efe4eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$107,000

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Avi Biopharma, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to subsets with effector cell function, and ultimately the retention of antigen-responsive lymphocytes with a memory cell phenotype. The initial increase of responsive lymphocytes is followed by an equally dramatic contraction of the responding population. The characteristic contraction of the number of responding lymphocytes that occurs following the antigen-driven expansion phase is caused, at the molecular level, by a change in the balance of intracellular proteins that are responsible for inhibiting or committing a cell to apoptosis via a programmed cell death pathway. Thus, during the initial antigen-driven expansion phase the level of anti-apoptotic protein(s) is increased and the cell is resistant to programmed cell death. Subsequently the level of these anti-apoptotic proteins declines placing the cell at risk for subsequent events conventionally termed activation-induced cell death. It is the hypothesis of this study that specific immune responses can be inhibited or destroyed at the clonal response level, by preventing the development of the increased level of anti-apoptotic protein(s) that develop during the initial response at the stage of antigen stimulation. Prevention of the production of the antigen response-induced anti-apoptotic proteins will place these cells at immediate risk for activation-induced cell death resulting in a selective deletion of the subset of antigen-responding lymphocytes. Such intervention will result in immunosuppression that is specific rather than global and will only affect those lymphocytes responding to antigen at the time anti-apoptotic protein production is prevented.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.